全文获取类型
收费全文 | 41675篇 |
免费 | 4365篇 |
国内免费 | 1130篇 |
专业分类
耳鼻咽喉 | 195篇 |
儿科学 | 1667篇 |
妇产科学 | 339篇 |
基础医学 | 5220篇 |
口腔科学 | 622篇 |
临床医学 | 4539篇 |
内科学 | 9727篇 |
皮肤病学 | 938篇 |
神经病学 | 2286篇 |
特种医学 | 683篇 |
外国民族医学 | 4篇 |
外科学 | 2783篇 |
综合类 | 6659篇 |
现状与发展 | 4篇 |
一般理论 | 1篇 |
预防医学 | 2948篇 |
眼科学 | 516篇 |
药学 | 3931篇 |
27篇 | |
中国医学 | 2913篇 |
肿瘤学 | 1168篇 |
出版年
2024年 | 199篇 |
2023年 | 946篇 |
2022年 | 1376篇 |
2021年 | 2171篇 |
2020年 | 2006篇 |
2019年 | 1745篇 |
2018年 | 1667篇 |
2017年 | 1775篇 |
2016年 | 1875篇 |
2015年 | 1685篇 |
2014年 | 3075篇 |
2013年 | 3231篇 |
2012年 | 2912篇 |
2011年 | 3043篇 |
2010年 | 2264篇 |
2009年 | 2180篇 |
2008年 | 2090篇 |
2007年 | 1899篇 |
2006年 | 1637篇 |
2005年 | 1450篇 |
2004年 | 1129篇 |
2003年 | 912篇 |
2002年 | 776篇 |
2001年 | 693篇 |
2000年 | 554篇 |
1999年 | 481篇 |
1998年 | 436篇 |
1997年 | 353篇 |
1996年 | 342篇 |
1995年 | 258篇 |
1994年 | 242篇 |
1993年 | 221篇 |
1992年 | 223篇 |
1991年 | 166篇 |
1990年 | 152篇 |
1989年 | 132篇 |
1988年 | 112篇 |
1987年 | 114篇 |
1986年 | 97篇 |
1985年 | 111篇 |
1984年 | 80篇 |
1983年 | 56篇 |
1982年 | 62篇 |
1981年 | 50篇 |
1980年 | 43篇 |
1979年 | 32篇 |
1978年 | 27篇 |
1977年 | 25篇 |
1976年 | 24篇 |
1974年 | 12篇 |
排序方式: 共有10000条查询结果,搜索用时 953 毫秒
41.
42.
43.
44.
《Value in health》2020,23(10):1340-1348
ObjectivesWe applied principles for conducting economic evaluations of factorial trials to a trial-based economic evaluation of a cluster-randomized 2 × 2 × 2 factorial trial. We assessed the cost-effectiveness of atorvastatin, omega-3 fish oil, and an action-planning leaflet, alone and in combination, from a UK National Health Service perspective.MethodsThe Atorvastatin in Factorial With Omega EE90 Risk Reduction in Diabetes (AFORRD) Trial randomized 800 patients with type 2 diabetes to atorvastatin, omega-3, or their respective placebos and randomized general practices to receive a leaflet-based action-planning intervention designed to improve compliance or standard care. The trial was conducted at 59 UK general practices. Sixteen-week outcomes for each trial participant were extrapolated for 70 years using the United Kingdom Prospective Diabetes Study Outcomes Model v2.01. We analyzed the trial as a 2 × 2 factorial trial (ignoring interactions between action-planning leaflet and medication), as a 2 × 2 × 2 factorial trial (considering all interactions), and ignoring all interactions.ResultsWe observed several qualitative interactions for costs and quality-adjusted life-years (QALYs) that changed treatment rankings. However, different approaches to analyzing the factorial design did not change the conclusions. There was a ≥99% chance that atorvastatin is cost-effective and omega-3 is not, at a £20 000/QALY threshold.ConclusionsAtorvastatin monotherapy was the most cost-effective combination of the 3 trial interventions at a £20 000/QALY threshold. Omega-3 fish oil was not cost-effective, while there was insufficient evidence to draw firm conclusions about action planning. Recently-developed methods for analyzing factorial trials and combining parameter and sampling uncertainty were extended to estimate cost-effectiveness acceptability curves within a 2x2x2 factorial design with model-based extrapolation. 相似文献
45.
目的分析研究绝经后女性2型糖尿病伴骨质疏松症患者骨密度与骨代谢指标的相关性。方法选取2013年10月至2017年05月于重庆医科大学附属第一医院内分泌内科住院的绝经后女性2型糖尿病患者385名。搜集其基本资料、骨代谢指标及骨密度等。根据T值将这些患者分为骨质疏松组(233例)、骨量减少组(101例)和骨量正常组(51例),比较三组间骨代谢指标的变化,并对骨密度(bone mineral density,BMD)与各项骨代谢指标进行相关性分析。结果 1型前胶原氨基末端前肽(Type I procollagen N-terminal propeptide,P1NP)、骨钙素(bone Gla protein,BGP)在骨质疏松组显著高于骨量减少组、骨量正常组(P0.05);随着骨密度的降低,1型胶原羧基端肽β特殊序列(β-Carboxyl terminal peptide,β-CTX)逐渐升高,骨质疏松组、骨量减少组与骨量正常组相比较差异有统计学意义(P0.05);Spearman等级相关分析示P1NP、BGP、β-CTX与骨密度呈负相关,25(OH)D_3与骨密度呈现正相关。结论绝经后女性2型糖尿病伴骨质疏松症患者骨密度与骨代谢指标有一定的相关性,有助于预测骨折风险并及时抗骨质疏松治疗。 相似文献
46.
47.
Fernand Lamisse 《Cahiers de Nutrition et de Diététique》2006,41(6):347-351
Many health-related research studies among Seventh-day Adventists (SDA) were published since 1958. Californian and Norwegian studies have shown that SDA have lower coronary mortality rates than the general population. This finding is usually attributed to the lifestyle advocated by the Seventh-day Adventist church with greater physical activity, lower median BMI, abstention from use of alcohol and tobacco, food habits characterized by a large intake of fruits, vegetables, cereal fiber, unsaturated fatty acids and a low consumption of saturated fats. The results about cancer incidence were discussed. Californian studies have shown significantly decreased relative risk in SDA than in the general population. Japanese studies have also reported lower risk of cancers in men with lifestyles similar to those of SDA. By contrast the Norwegian study of SDA has shown that the risk of cancer seems to be similar to that of the general population. Some studies reported a greater prevalence of type 2 diabetes in the non vegetarian SDA than the vegetarian. Compared with vegetarian, non vegetarian SDA reported more medication use, more chronic diseases, more hospitalizations and surgeries. Lifestyle choices of SDA as above described could prevent a great many coronary artery disease and type 2 diabetes. This lifestyle is now emphasized by French PNNS. 相似文献
48.
Active production of anti-human T-lymphotropic virus type I (HTLV-I) IgM antibody in HTLV-I-associated myelopathy 总被引:2,自引:0,他引:2
Kunihiko Nagasato Tatsufumi Nakamura Ohishi Kiyosumi Kohji Shibayama Masakatsu Motomura Ichinose Katsuhiro Mitsuhiro Tsujihata Shigenobu Nagataki 《Journal of neuroimmunology》1991,32(2):105-109
We investigated the presence of anti-human T-lymphotropic virus type I (HTLV-I) IgM in sera and cerebrospinal fluid from patients with HTLV-I-associated myelopathy (HAM) by Western blot analysis. Analyses of 36 serum samples revealed that most patients (31/36; 86.1%) had anti-HTLV-I IgM, whereas only four of 23 (17.4%) HTLV-I carriers had it. In studies of cerebrospinal fluid, anti-HTLV-I IgM was detected in 24 of 36 (66.7%) HAM patients, whereas none was detected in nine HTLV-I carriers. The differences were statistically significant (p less than 0.01). These results suggest that persistent active replication of HTLV-I occurs in the central nervous system as well as in the peripheral blood of HAM patients, and may contribute to the development of HAM. 相似文献
49.
H J Schluesener 《Journal of neuroscience research》1991,28(2):310-314
The transforming growth factors type beta 1, beta 2, and beta 1.2 suppress multidrug transport in human pat-1 glioblastoma cells and even in cells that strongly over-express mdr genes and are resistant to inhibition of multidrug transport by chemosensitizers. Thus, inhibition of multidrug transport by cytokines might be a new approach to increase cellular accumulation of chemotherapeutic agents in multidrug resistant glial tumor cells. Interestingly, a member of the more distantly related decapentaplegic subgroup of transforming growth factors, the bone morphogenetic protein BMP 2, did not inhibit multidrug transport. 相似文献
50.